Megna Health Announces Submission of Application to the FDA for Emergency Use Authorization of its Rapid COVID-19 IgG & IgM Antibody Test for Prescription Home Use
Share Article
The test is performed in 15 minutes with one drop of fingerstick sample with no additional equipment needed. EXTON, Pa. (PRWEB) May 24, 2021 Megna Health, a U.S. manufacturer of Rapid COVID Tests based in Exton, Pennsylvania, announced that it has filed a U.S. Food and Drug Administration (FDA) EUA (Emergency Use Authorization) extension for Prescription Home Use for its Rapid COVID-19 IgG/IgM Antibody Test and is preparing for product launch. The test is performed in 15 minutes with one drop of fingerstick sample with no additional equipment needed.
US Based Megna Health s Rapid COVID-19 Antibody Test Receives Point of Care Emergency Use Authorization AHOD Co. will provide sales, logistic, and distribution support so that tests will be available where they are needed most.
April 29, 2021 10:19 ET | Source: AHOD AHOD Gainesville, Florida, UNITED STATES
EXTON, PA., GAINESVILLE, FLA., April 29, 2021 (GLOBE NEWSWIRE) Megna Health announced today that its Rapid COVID-19 IgM/IgG Antibody Combo Test, previously authorized for use under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization, is now available for Point of Care Settings. The test can now be administered in CLIA-waived settings using fingerstick whole blood to detect COVID-19 antibodies.
Megna Health Receives Point of Care With Fingerstick, Emergency Use Authorization from the FDA for its Rapid COVID-19 IgM/IgG Combo Antibody Test
Share Article
The test can now be administered in CLIA-waived settings using fingerstick whole blood to detect COVID-19 antibodies
This is the next step of several in the Megna Health pipeline to increase access to affordable rapid testing. EXTON, Pa. (PRWEB) April 23, 2021 Megna Health announced today that its Rapid COVID-19 IgM/IgG Test, previously authorized for use under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization, is now available for Point of Care Settings. The test can now be administered in CLIA-waived settings using fingerstick whole blood to detect COVID-19 antibodies.
Share this article
Share this article
ResearchAndMarkets.com s offering.
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global COVID-19 Diagnostics Market Report
The global COVID-19 diagnostics market by revenue is expected to register a negative CAGR of (9%) during the period 2021-2026.
The RT-PCR testing segment constituted over 75% of the global COVID diagnostics market share. The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing.
Veteran-Owned Company & US Manufacturer Team Up To Distribute Millions of Rapid COVID-19 Tests Nationwide yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.